{"id":2648,"date":"2026-11-05T07:00:43","date_gmt":"2026-11-04T23:00:43","guid":{"rendered":"https:\/\/www.hanchorbio.com\/?post_type=news&p=2648"},"modified":"2026-11-04T17:37:09","modified_gmt":"2026-11-04T09:37:09","slug":"hanchorbio-and-kaohsiung-medical-university-hospital-sign-mou-to-strengthen-cancer-clinical-research-collaboration","status":"publish","type":"news","link":"https:\/\/www.hanchorbio.com\/en\/news\/hanchorbio-and-kaohsiung-medical-university-hospital-sign-mou-to-strengthen-cancer-clinical-research-collaboration\/","title":{"rendered":"HanchorBio and Kaohsiung Medical University Hospital Sign MOU to Strengthen Cancer Clinical Research Collaboration"},"content":{"rendered":"

HanchorBio and Kaohsiung Medical University Hospital Sign MOU to Strengthen Cancer Clinical Research Collaboration<\/strong><\/h2>\n

Combining innovative drug development and clinical expertise to explore future medical research opportunities, with a focus on patient safety and research collaboration<\/em><\/strong><\/h3>\n

\u00a0<\/strong><\/p>\n

[Taipei, Shanghai, San Francisco | November 5, 2026] \u2013<\/strong> HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases, today announced the signing of a Memorandum of Understanding (MOU) with Kaohsiung Medical University Hospital (KMUH). The collaboration combines HanchorBio’s expertise in innovative drug development and clinical development with KMUH’s clinical and research expertise in gastrointestinal oncology to explore potential opportunities for future clinical research. Both parties aim to generate additional scientific evidence in cancer research through clinical studies, while maintaining rigorous standards of patient safety, medical ethics, and regulatory compliance.<\/p>\n

\"\"<\/strong><\/p>\n

The MOU represents an important step toward establishing a foundation for further collaboration between HanchorBio and KMUH in clinical research and medical innovation. Through professional exchanges and resource integration, both parties intend to evaluate appropriate directions for research collaboration and strengthen the connection between innovative drug development and clinical needs.<\/p>\n

 <\/p>\n

Focusing on Clinical Needs in Cancer and Strengthening Research Collaboration<\/strong><\/p>\n

KMUH brings extensive clinical expertise in the treatment and medical research of gastrointestinal cancers, while HanchorBio focuses on innovative drug development and clinical development in oncology and immune-mediated diseases. By combining their respective expertise in clinical medicine and biotechnology research, both parties aim to explore appropriate models for research collaboration through ongoing dialogue and evaluation, in accordance with Taiwan’s regulatory and medical ethics requirements.<\/p>\n

 <\/p>\n

Professor Jaw-Yuan Wang, President of KMUH, noted that the Taiwan government’s “Healthy Taiwan” policy aims to improve public health and strengthen cancer prevention and control efforts, while medical institutions must continue to enhance the quality of clinical care and research. He emphasized that the primary purpose of the MOU is to establish a framework for communication and evaluation of clinical research-related matters between the two parties, with the scope of collaboration focused on exploring potential clinical research opportunities. Should specific research projects be proposed in the future, each will be evaluated objectively and prudently based on its research design and scientific evidence, and will undergo the necessary review and approval procedures in accordance with applicable regulations to ensure research quality, participant safety, and the protection of participants’ rights and interests.<\/p>\n

 <\/p>\n

Advances in Innovative Immunotherapy Research: Connecting Science with Clinical Needs<\/strong><\/p>\n

HanchorBio continues to develop innovative immunotherapies through its proprietary FBDB\u2122 multifunctional biologics platform. Its lead investigational candidate is designed to block the CD47\u2013SIRP\u03b1 immune checkpoint to enhance macrophage-mediated antitumor immune responses and explore the interplay between innate and adaptive immunity. Related preclinical findings have been published in the international scientific journal Journal of Hematology & Oncology<\/em>, providing an important scientific foundation for further research.<\/p>\n

 <\/p>\n

The investigational candidate is currently being evaluated in Phase 1b\/2a clinical trials in Taiwan, the United States, and other regions, covering solid tumors including gastric cancer, gastroesophageal junction cancer, and colorectal cancer. Clinical findings remain preliminary, and the safety and efficacy of the investigational therapy have yet to be confirmed in subsequent studies. These findings will inform the evaluation of future clinical development strategies.<\/p>\n

 <\/p>\n

Exploring Future Collaboration with Patient Safety and Medical Ethics at the Core<\/strong><\/p>\n

Under the MOU, HanchorBio and KMUH will engage in discussions and evaluations of potential research directions and implementation approaches based on clinical needs. By leveraging their respective expertise and resources, both parties aim to progressively strengthen their collaboration and contribute to the advancement of clinical research and medical science.<\/p>\n

 <\/p>\n

“The value of innovative drug development lies not only in continued scientific progress, but also in addressing real-world clinical needs,” said Scott Liu, Ph.D., Chairman and Chief Executive Officer of HanchorBio. “Signing this MOU with KMUH represents an important step in strengthening HanchorBio’s collaboration with medical institutions in Taiwan. We look forward to combining our respective expertise to continue exploring appropriate directions for clinical research collaboration and contributing to the advancement of medical research.”<\/p>\n

 <\/p>\n

Connecting Clinical Care with Innovative Drug Development to Strengthen Collaboration<\/strong><\/p>\n

The signing of this MOU establishes a foundation for further engagement and collaboration between HanchorBio and KMUH. Moving forward, both parties will continue exploring opportunities for clinical research collaboration, facilitating professional exchanges between medical institutions and the biotechnology industry, and supporting the advancement of medical research in accordance with applicable regulatory and medical research ethics requirements.<\/p>\n

 <\/p>\n

HanchorBio remains committed to innovative drug development and global clinical development. Through continued collaboration with medical institutions and research teams, the Company aims to deepen its understanding of clinical needs, strengthen the connection between scientific research and clinical care, and establish a broader foundation for future medical innovation.<\/p>\n

 <\/p>\n

Looking ahead, HanchorBio will continue advancing its global clinical development programs, including planned randomized clinical studies in second-line gastric and gastroesophageal junction cancers and ongoing combination studies across multiple solid tumor types. In parallel, the Company will continue strengthening collaborations with qualified medical institutions and research teams, combining innovative drug development capabilities with clinical expertise to generate additional scientific evidence that may inform future clinical development and medical research.<\/p>\n

 <\/p>\n

About HanchorBio<\/strong><\/p>\n

HanchorBio, Inc. (TWSE: 7827) is a global clinical-stage biotechnology company developing next-generation biologics for cancer and immune-mediated diseases through its proprietary FBDB\u2122 platform. Powered by multifunctional protein-engineering technology, its pipeline includes HCB101, HCB301, and HCB303. All three candidates are investigational products that have not received marketing approval in Taiwan or any other country.<\/p>\n

With operations across Taipei, the San Francisco Bay Area, and Shanghai, HanchorBio is committed to reimagining immunotherapy and creating new treatment possibilities for patients worldwide. For more information, please visit: https:\/\/www.HanchorBio.com<\/a>.<\/p>\n

 <\/p>\n

Important Notice<\/strong><\/p>\n

This MOU does not constitute approval of or a commitment to any specific clinical trial or treatment. Any clinical research involving investigational products conducted by HanchorBio and KMUH must receive prior approval from the relevant regulatory authorities and Institutional Review Boards (IRBs). The safety and efficacy of HanchorBio’s investigational products have not been established. Patients seeking treatment should consult their treating physicians.<\/p>\n

 <\/p>\n

Forward-Looking Statements<\/strong><\/p>\n

This press release contains forward-looking statements, including statements regarding potential future collaboration between HanchorBio and KMUH and plans for clinical research cooperation. Any subsequent collaboration or research activities will be subject to applicable laws and regulations, medical ethics requirements, and relevant institutional procedures. Actual activities and timelines may be adjusted due to regulatory, clinical, operational, and other factors.<\/p>\n

HanchorBio undertakes no obligation to update forward-looking statements except as required by applicable law. HanchorBio is solely responsible for statements in this press release concerning its products, operations, and research and development plans.<\/p>\n

 <\/p>\n

Investor & Media Contact:<\/strong><\/p>\n

Email: IRPR@hanchorbio.com<\/a><\/p>\n

HanchorBio Business Development Contact: <\/strong><\/p>\n

Email: BD@HanchorBio.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

HanchorBio announced the signing of a Memorandum of Understanding (MOU) with Kaohsiung Medical University Hospital (KMUH). The collaboration combines HanchorBio’s expertise in innovative drug development and clinical development with KMUH’s clinical and research expertise in gastrointestinal oncology to explore potential opportunities for future clinical research. Both parties aim to generate additional scientific evidence in cancer research through clinical studies, while maintaining rigorous standards of patient safety, medical ethics, and regulatory compliance.<\/p>\n","protected":false},"featured_media":2647,"template":"","news-category":[34,37],"class_list":["post-2648","news","type-news","status-publish","has-post-thumbnail","hentry","news-category-development-progress","news-category-market-and-licensing"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news\/2648","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/types\/news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/media\/2647"}],"wp:attachment":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/media?parent=2648"}],"wp:term":[{"taxonomy":"news-category","embeddable":true,"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news-category?post=2648"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}